HEPA — Hepion Pharmaceuticals Balance Sheet
0.000.00%
- $0.80m
- $0.39m
- 17
- 52
- 21
- 19
Annual balance sheet for Hepion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 40.7 | 91.3 | 51.2 | 14.8 | 0.406 |
| Prepaid Expenses | |||||
| Total Current Assets | 42.6 | 97.5 | 56.5 | 17.5 | 1.61 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.665 | 0.456 | 0.132 | 0.242 | 0 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 48.6 | 104 | 60.2 | 18.1 | 1.61 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.66 | 8.21 | 7.89 | 5.29 | 3.14 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.12 | 10.6 | 10.4 | 10.8 | 3.48 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 40.5 | 93 | 49.9 | 7.28 | -1.86 |
| Total Liabilities & Shareholders' Equity | 48.6 | 104 | 60.2 | 18.1 | 1.61 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |